Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$3.44M-$3.44MN/M vs Q3 2024 EPS Diluted-$0.07-$0.07N/M vs Q3 2024 Operating Income-$3,488,843N/M Operating Cash Flowderived-$3,484,364N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end